Cronkhite-Canada Syndrome: A Diagnostic Challenge and Management With Vedolizumab

克朗凯特-加拿大综合征:诊断挑战及维多珠单抗治疗

阅读:1

Abstract

BACKGROUND Cronkhite-Canada syndrome (CCS) is a rare, nonhereditary gastrointestinal polyposis syndrome characterized by diffuse polyps, diarrhea, malnutrition, and ectodermal changes. It can mimic inflammatory bowel disease (IBD), leading to misdiagnosis and delayed treatment. Here, we present a case of CCS that was initially thought to be Crohn's disease, managed with vedolizumab, and ultimately required total parenteral nutrition (TPN) due to severe malnutrition. CASE REPORT A 65-year-old man presented with a history of 2 months of watery diarrhea, weight loss, postprandial abdominal pain, dysgeusia, and nail dystrophy. He was initially diagnosed with Crohn's disease based on colonoscopy and biopsies. His symptoms were initially managed with prednisone and vedolizumab. However, 8 months later, he developed worsening dysgeusia, anorexia, and further weight loss. A follow-up esophagogastroduodenoscopy (EGD) showed large nodular polyps in the stomach and duodenum, with chronic inflammation, epithelial hyperplasia, and mucosal edema on biopsy. In a multidisciplinary review, the clinical picture was deemed more consistent with CCS rather than Crohn's disease. Vedolizumab was continued due to partial symptomatic relief. Endoscopic or surgical gastrostomy was deferred due to severe malnutrition and extensive gastric involvement, and TPN was initiated. CONCLUSIONS This case highlights the diagnostic complexity and clinical severity of CCS, which can closely mimic IBD. Although the patient had a partial response to vedolizumab, the progression of disease led to severe malnutrition requiring TPN. Early recognition and aggressive nutritional and medical management are essential for managing this debilitating condition.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。